Sana Biotechnology — Third Quarter 2026 Earnings Summary

Sana Biotechnology reported a net income of $20.4 million for the third quarter of 2026, driven primarily by a $55.5 million non-cash gain related to changes in the fair value of Cobalt contingent consideration. The company maintains a cash position of $121.7 million as of September 30, 2026, providing a runway into mid-2027. Clinical progress includes plans to file an IND and initiate a Phase 1/2 trial for SC451 in type 1 diabetes later in 2026, alongside updates on SG293 for non-Hodgkin lymphoma and SG227 for multiple myeloma. Long-term data from an investigator-sponsored study on UP421 demonstrated the survival and function of hypoimmune-modified islet cells in a type 1 diabetes patient for 14 months without immunosuppression, with results published in The New England Journal of Medicine.